{
  "meta": {
    "title": "24_Basics_Of_Genetics_-_Nucleotide_Metabolism_And_Its_Disorders",
    "url": "https://brainandscalpel.vercel.app/24-basics-of-genetics-nucleotide-metabolism-and-its-disorders-90a59067.html",
    "scrapedAt": "2025-11-30T12:26:42.837Z"
  },
  "questions": [
    {
      "text": "Which of the following nitrogenous base contain amino group on the 6th carbon?",
      "choices": [
        {
          "id": 1,
          "text": "Adenine"
        },
        {
          "id": 2,
          "text": "Guanine"
        },
        {
          "id": 3,
          "text": "Cytosine"
        },
        {
          "id": 4,
          "text": "Thymine"
        }
      ],
      "correct_choice_id": 1,
      "solution": "<p>Adenine has an <strong>amino (NH<sub>2</sub>)</strong> group on the <strong>6<sup>th</sup>&nbsp;carbon.</strong>&nbsp;</p><img src=\"https://dhmbxeygs57ff.cloudfront.net/uploads/f388f06ba5134cf0880a290c3c294c3fx1280x2236.JPEG\" alt=\"Explanation Image\">",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MB2113",
      "difficulty": "medium"
    },
    {
      "text": "Which of the following process do not contribute to purine nucleotide biosynthesis?",
      "choices": [
        {
          "id": 1,
          "text": "Synthesis from amphibolic intermediates"
        },
        {
          "id": 2,
          "text": "Phosphoribosylation of purines"
        },
        {
          "id": 3,
          "text": "Phosphorylation of purine nucleosides"
        },
        {
          "id": 4,
          "text": "Phosphoribosylation of purine nucleosides"
        }
      ],
      "correct_choice_id": 4,
      "solution": "<p>Phosphoribosylation of purine nucleosides <strong>does not contribute</strong> to <strong>purine nucleotide biosynthesis.</strong></p>\n<p>The three processes that contribute to purine nucleotide biosynthesis in the order of decreasing importance are :</p>\n<ul>\n<li>Synthesis from amphibolic intermediates.</li>\n<li>Phosphoribosylation of purine bases.</li>\n<li>Phosphorylation of purine nucleosides.</li>\n</ul>\n<p><strong>De novo </strong><span>purine nucleotide synthesis doesn't occur</span> in the <strong>brain,</strong> bone marrow, <strong>erythrocytes,</strong> and leucocytes.</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MB2329",
      "difficulty": "medium"
    },
    {
      "text": "Which of the following molecule doesn't contribute to the synthesis of a purine ring?",
      "choices": [
        {
          "id": 1,
          "text": "CO2"
        },
        {
          "id": 2,
          "text": "Aspartate"
        },
        {
          "id": 3,
          "text": "Glutamine"
        },
        {
          "id": 4,
          "text": "Lysine"
        }
      ],
      "correct_choice_id": 4,
      "solution": "<p><strong>Lysine</strong> does not contribute to the synthesis of a purine ring.</p>\n<p><strong>Glycine, aspartate</strong> &amp;<strong> glutamine</strong> are the amino acids that contribute to synthesizing a <strong>purine</strong> ring. CO<sub>2</sub>, N10-Formyl-THFA and N5N10-Methenyl-THFA are the other molecules that influence the structure.</p>\n<p>The image below shows the origin of the atoms in the purine ring:</p><img src=\"https://dhmbxeygs57ff.cloudfront.net/uploads/fbb4c3712c744d259a84ad377a9c2ec9x1280x1216.JPEG\" alt=\"Explanation Image\"><p>Note: <strong>Glycine</strong> does not participate in pyrimidine ring synthesis.</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MB2333",
      "difficulty": "easy"
    },
    {
      "text": "What is the rate-limiting step of de novo purine synthesis?",
      "choices": [
        {
          "id": 1,
          "text": "PRPP to  Phosphoribosyl amine by PRPP glutamyl amidotransferase"
        },
        {
          "id": 2,
          "text": "PRPP to Phosphoribosyl amine by PRPP synthetase"
        },
        {
          "id": 3,
          "text": "Ribose 5-phosphate to PRPP by  PRPP synthetase"
        },
        {
          "id": 4,
          "text": "Ribose 5-phosphate to PRPP by PRPP glutamyl amidotransferase"
        }
      ],
      "correct_choice_id": 1,
      "solution": "<p>The <strong>rate-limiting step </strong>of de novo purine synthesis is the conversion of <strong>5-phosphoribosyl-1-pyrophosphate</strong> (PRPP) to <strong>phosphoribosylamine</strong> by <strong>PRPP Glutamyl amidotransferase.</strong></p>\n<p>The first intermediate formed in the de novo pathway for purine biosynthesis is 5-phosphoribosyl 1-pyrophosphate (PRPP). The rate-limiting enzyme is PRPP Glutamyl amidotransferase. This is the <strong>committed step</strong> in purine nucleotide biosynthesis.</p>\n<p>Note: PRPP Glutamyl amidotransferase is <strong>activated</strong> by<strong> PRPP</strong> and <strong>glutamine</strong> and<strong> inhibited</strong> by <strong>A</strong><strong>MP</strong> and<strong> GMP.</strong></p><hr><h3>Related Pearl: Enzymes of Purine Synthesis Pathway and Their Regulators</h3><table>\n<tbody>\n<tr>\n<td>\n<p><strong>Enzymes</strong></p>\n</td>\n<td>\n<p><strong>Regulators</strong></p>\n</td>\n</tr>\n<tr>\n<td>\n<p>PRPP Glutamyl Amidotransferase</p>\n</td>\n<td>\n<p>Inhibited by Amp &amp; GMP</p>\n<p>Activator &nbsp;PRPP</p>\n<p>Activated by Glutamine</p>\n<p>Diazanorleucine(inhibitor)</p>\n</td>\n</tr>\n<tr>\n<td>\n<p>PRPP synthetase</p>\n</td>\n<td>\n<p>Activator pi</p>\n<p>Inhibitors &nbsp;purine ribonucleotides</p>\n</td>\n</tr>\n<tr>\n<td>\n<p>Formyltransferase</p>\n</td>\n<td>\n<p>Methotrexate, Anti-folate drugs</p>\n</td>\n</tr>\n<tr>\n<td>\n<p>VI Synthetase</p>\n</td>\n<td>\n<p>Azaserine</p>\n</td>\n</tr>\n<tr>\n<td>\n<p>Adenylosuccinase ,IMP Dehydrogenase</p>\n</td>\n<td>\n<p>6-mercaptopurine</p>\n</td>\n</tr>\n<tr>\n<td>\n<p>IMP Dehydrogenase</p>\n</td>\n<td>\n<p>mycophenolic acid</p>\n</td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div>\n<p>&nbsp;</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MB2336",
      "difficulty": "medium"
    },
    {
      "text": "The parent purine nucleotide made from de novo purine synthesis is ______",
      "choices": [
        {
          "id": 1,
          "text": "AMP"
        },
        {
          "id": 2,
          "text": "GMP"
        },
        {
          "id": 3,
          "text": "IMP"
        },
        {
          "id": 4,
          "text": "TMP"
        }
      ],
      "correct_choice_id": 3,
      "solution": "<p><strong>Inosine monophosphate</strong> <strong>(IMP)</strong> is the <strong>parent purine nucleotide</strong> made from de novo purine synthesis.</p>\n<p><strong>Ribose 5-phosphate</strong> is converted to inosine monophosphate (IMP) by series of reactions. The <strong>regulatory enzymes</strong> of purine synthesis are</p>\n<ul>\n<li>PRPP Synthetase</li>\n<li>PRPP glutamyl amidotransferase</li>\n</ul>\n<p>The rate-limiting enzyme is <strong>PRPP glutamyl amidotransferase.</strong></p>\n<p>Following the synthesis of IMP, separate branches lead to <strong>AMP</strong> and <strong>GMP</strong> synthesis.</p><hr><h3>Related Pearl: Enzymes of Purine Synthesis Pathway and Their Regulators</h3><table>\n<tbody>\n<tr>\n<td>\n<p><strong>Enzymes</strong></p>\n</td>\n<td>\n<p><strong>Regulators</strong></p>\n</td>\n</tr>\n<tr>\n<td>\n<p>PRPP Glutamyl Amidotransferase</p>\n</td>\n<td>\n<p>Inhibited by Amp &amp; GMP</p>\n<p>Activator &nbsp;PRPP</p>\n<p>Activated by Glutamine</p>\n<p>Diazanorleucine(inhibitor)</p>\n</td>\n</tr>\n<tr>\n<td>\n<p>PRPP synthetase</p>\n</td>\n<td>\n<p>Activator pi</p>\n<p>Inhibitors &nbsp;purine ribonucleotides</p>\n</td>\n</tr>\n<tr>\n<td>\n<p>Formyltransferase</p>\n</td>\n<td>\n<p>Methotrexate, Anti-folate drugs</p>\n</td>\n</tr>\n<tr>\n<td>\n<p>VI Synthetase</p>\n</td>\n<td>\n<p>Azaserine</p>\n</td>\n</tr>\n<tr>\n<td>\n<p>Adenylosuccinase ,IMP Dehydrogenase</p>\n</td>\n<td>\n<p>6-mercaptopurine</p>\n</td>\n</tr>\n<tr>\n<td>\n<p>IMP Dehydrogenase</p>\n</td>\n<td>\n<p>mycophenolic acid</p>\n</td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div>\n<p>&nbsp;</p><hr><h3>Related Pearl: Enzymes and Steps Involved in Purine Degradation</h3><table>\n<tbody>\n<tr>\n<td>\n<p>Enzymes</p>\n</td>\n<td>\n<p>Reaction</p>\n</td>\n</tr>\n<tr>\n<td>\n<p>AMP deaminase</p>\n</td>\n<td>\n<p>AMP to IMP</p>\n</td>\n</tr>\n<tr>\n<td>\n<p>Adenosine deaminase</p>\n</td>\n<td>\n<p>Adenosine to Inosine</p>\n</td>\n</tr>\n<tr>\n<td>\n<p>5'-nucleotidase</p>\n</td>\n<td>\n<p>IMP &amp; GMP to Inosine &amp; Guanosine respectively</p>\n</td>\n</tr>\n<tr>\n<td>\n<p>Purine nucleoside phosphorylase</p>\n</td>\n<td>\n<p>Inosine &amp; Guanosine to Hypoxanthine &amp; guanine respectively</p>\n</td>\n</tr>\n<tr>\n<td>\n<p>Xanthine oxidase</p>\n</td>\n<td>\n<p>Hypoxanthine to Xanthine &amp; Xanthine to uric acid</p>\n</td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MB2330",
      "difficulty": "easy"
    },
    {
      "text": "A 4-year-old girl is started on rasburicase before initiating chemotherapy for acute lymphoblastic leukemia. What is the end product of the breakdown of purine nucleotides in her?",
      "choices": [
        {
          "id": 1,
          "text": "Allantoin"
        },
        {
          "id": 2,
          "text": "Amino acid"
        },
        {
          "id": 3,
          "text": "Ammonia"
        },
        {
          "id": 4,
          "text": "Uric acid"
        }
      ],
      "correct_choice_id": 1,
      "solution": "<p><strong>Allantoin</strong> is the end product of purine catabolism in a patient on <strong>rasburicase</strong>, a recombinant uricase enzyme.</p>\n<p><strong>Uric acid</strong> is the natural <strong>end product</strong> of <strong>purine catabolism </strong>in humans. So, in conditions with <strong>high cell turnover</strong>, such as leukemia, lymphomas, and other malignancies, there is increased uric acid production. To prevent <strong>hyperuricemia</strong>, medications such as <strong>rasburicase</strong> are administered prophylactically. It is a recombinant uricase enzyme that <strong>converts uric acid</strong> to a water-soluble end product, <strong>allantoin</strong> that is easily excreted by the kidneys.</p>\n<p>Note: In mammals other than primates, uricase is naturally occurring and allantoin is the end product of purine catabolism.</p><hr><h3>Related Pearl: Enzymes and Steps Involved in Purine Degradation</h3><table>\n<tbody>\n<tr>\n<td>\n<p>Enzymes</p>\n</td>\n<td>\n<p>Reaction</p>\n</td>\n</tr>\n<tr>\n<td>\n<p>AMP deaminase</p>\n</td>\n<td>\n<p>AMP to IMP</p>\n</td>\n</tr>\n<tr>\n<td>\n<p>Adenosine deaminase</p>\n</td>\n<td>\n<p>Adenosine to Inosine</p>\n</td>\n</tr>\n<tr>\n<td>\n<p>5'-nucleotidase</p>\n</td>\n<td>\n<p>IMP &amp; GMP to Inosine &amp; Guanosine respectively</p>\n</td>\n</tr>\n<tr>\n<td>\n<p>Purine nucleoside phosphorylase</p>\n</td>\n<td>\n<p>Inosine &amp; Guanosine to Hypoxanthine &amp; guanine respectively</p>\n</td>\n</tr>\n<tr>\n<td>\n<p>Xanthine oxidase</p>\n</td>\n<td>\n<p>Hypoxanthine to Xanthine &amp; Xanthine to uric acid</p>\n</td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MB2343",
      "difficulty": "medium"
    },
    {
      "text": "Which of the following diseases is not associated with purine degradation?",
      "choices": [
        {
          "id": 1,
          "text": "Gout"
        },
        {
          "id": 2,
          "text": "Severe combined immunodeficiency syndrome"
        },
        {
          "id": 3,
          "text": "Purine nucleoside phosphorylase deficiency"
        },
        {
          "id": 4,
          "text": "Orotic aciduria"
        }
      ],
      "correct_choice_id": 4,
      "solution": "<p><strong>Orotic aciduria</strong> is not associated with<strong> purine degradation.</strong> </p>\n<p>Orotic aciduria is an autosomal recessive disorder caused by the deficiency of <strong>orotidylate decarboxylase</strong> or <strong>UMP synthase.</strong> It is the<strong> most common </strong>metabolic error in the synthesis of <strong>pyrimidines</strong>.</p>\n<p>Gout, severe combined immunodeficiency syndrome (SCID) and purine nucleoside phosphorylase (PNP) deficiency are associated with<strong> purine degradation.</strong></p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MB2345",
      "difficulty": "medium"
    },
    {
      "text": "Which of the following bases can't be salvaged to the corresponding nucleotide?",
      "choices": [
        {
          "id": 1,
          "text": "Uracil"
        },
        {
          "id": 2,
          "text": "Adenine"
        },
        {
          "id": 3,
          "text": "Hypoxanthine"
        },
        {
          "id": 4,
          "text": "Guanine"
        }
      ],
      "correct_choice_id": 1,
      "solution": "<p><strong>Uracil</strong> cannot be salvaged to its corresponding nucleotide.</p>\n<p>Pyrimidine bases <strong>cannot</strong> be <strong>salvaged</strong> to their corresponding nucleotides. <strong>Purine bases</strong> that are <strong>salvaged</strong> are <strong>adenine, hypoxanthine, and guanine.</strong></p>\n<p>Salvage pathway - This pathway involves the conversion of purines to nucleosides and later to mononucleotides. It requires less energy than de novo synthesis. It usually occurs in places where de novo synthesis of<strong> purines </strong>is <strong>absent </strong>like<strong> brain, erythrocytes, etc. </strong>The enzymes that catalyze this reaction are : </p>\n<ul>\n<li>Adenine phosphoribosyltransferase (APRT)</li>\n<li>Hypoxanthine-guanine phosphoribosyltransferase (HGPRT).</li>\n</ul><hr><h3>Related Pearl: Purine salvage deficiencies: Lesch-Nyhan syndrome and Adenosine deaminase deficiency(SCID)</h3><p><strong>Severe Combined Immunodeficiency(SCID):</strong></p>\n<p><strong>Adenosine deaminase</strong>&nbsp;enzyme deficiency is one of the major cause of SCID. It is also called as&nbsp;<strong>Glanzmann&ndash;Riniker syndrome.</strong></p>\n<p>SCID patients are usually affected by severe bacterial, viral, or fungal infections early in life and often present with interstitial lung disease, chronic diarrhea, and failure to thrive.</p>\n<p><strong>Lesch-Nyhan syndrome:</strong></p>\n<p>It is due to deficiency of the enzyme<strong> Hypoxanthine-guanine phosphoribosyltransferase(HGPRT). </strong>It is an X-linked recessive disease.</p>\n<p>Clinical features:</p>\n<ul>\n<li><span class=\"fontstyle0\">Intellectual disability</span></li>\n<li><span class=\"fontstyle0\">Self-mutilation</span></li>\n<li><span class=\"fontstyle0\">Aggression</span></li>\n<li>Hyperuricemia&nbsp;</li>\n<li><span class=\"fontstyle0\">Gout<br /></span></li>\n</ul>\n<p><span class=\"fontstyle0\">Treatment:</span></p>\n<ul>\n<li><span class=\"fontstyle0\">Allopurinol</span></li>\n<li><span class=\"fontstyle0\">Febuxostat</span></li>\n</ul>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MB2341",
      "difficulty": "medium"
    },
    {
      "text": "A 4-year-old child presents with hyperuricemia and delayed developmental milestones. He also has the habit of biting his lips, fingers, and feet because of which he is always strapped to the bed. Urine examined showed orange sands. Which is the most probable enzyme deficiency?",
      "choices": [
        {
          "id": 1,
          "text": "Adenine phosphoribosyltransferase"
        },
        {
          "id": 2,
          "text": "Hypoxanthine-guanine phosphoribosyltransferase"
        },
        {
          "id": 3,
          "text": "Adenosine Deaminase"
        },
        {
          "id": 4,
          "text": "Purine nucleoside phosphorylase"
        }
      ],
      "correct_choice_id": 2,
      "solution": "<p>The given clinical scenario is highly suggestive of <strong>Lesch-Nyhan syndrome</strong>. It is caused due to the <strong>complete </strong>deficiency of<strong> Hypoxanthine-guanine phosphoribosyltransferase (HGPRT).</strong></p>\n<p><strong>Lesch-Nyhan syndrome</strong> is an X-linked recessive disorder. This deficiency results in an <strong>inability to salvage</strong> hypoxanthine or guanine, from which excessive amounts of<strong> uric acid </strong>is produced and excreted in urine as<strong> orange sands.</strong></p>\n<p>Clinical features include <strong>compulsive self-mutilation</strong>, <strong>hyperuricemia</strong>, intellectual disability, delayed milestones, dystonic movements and megaloblastic anemia.</p>\n<p>Diagnosis is made by deficient HGPRTase enzyme activity in the erythrocyte. <strong>Partial deficiency</strong> of HGPRTase cause <strong>Kelley-Seegmiller syndrome.</strong></p>\n<p>Other options:</p>\n<p>Option A: Adenine phosphoribosyltransferase<strong> </strong>enzyme deficiency causes urinary <strong>calculus formation with crystalluria.</strong></p>\n<p>Option C: Adenosine deaminase enzyme deficiency is one of the  2nd major cause of <strong>SCID.</strong></p>\n<p>Option D: Purine nucleoside phosphorylase causes<strong> a severe deficiency of T cells</strong> but B cells are normal.</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MB2342",
      "difficulty": "easy"
    },
    {
      "text": "Which of the following is not required for pyrimidine ring synthesis?",
      "choices": [
        {
          "id": 1,
          "text": "Aspartate"
        },
        {
          "id": 2,
          "text": "CO2"
        },
        {
          "id": 3,
          "text": "Glycine"
        },
        {
          "id": 4,
          "text": "Glutamine"
        }
      ],
      "correct_choice_id": 3,
      "solution": "<p><strong>Glycine</strong> is not required for pyrimidine ring synthesis.</p>\n<p>The sources of the atoms in the pyrimidine ring are <strong>glutamine, CO2, </strong>and <strong>aspartic acid</strong>.  The pyrimidine ring is synthesized before being attached to <strong>ribose 5-phosphate</strong>, which is donated by <strong>PRPP.</strong></p>\n<p>Note: Glycine is required in the synthesis of <strong>purine ring</strong> and not in the pyrimidine synthesis.</p>\n<p>The image below shows the origin of the various atoms in the pyrimidine ring:</p><img src=\"https://dhmbxeygs57ff.cloudfront.net/uploads/5e1a18e9dd2749d0879d61bc87c0aa71x1280x835.JPEG\" alt=\"Explanation Image\">",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MB2346",
      "difficulty": "easy"
    },
    {
      "text": "The only mitochondrial step in pyrimidine synthesis is catalyzed by the enzyme ________",
      "choices": [
        {
          "id": 1,
          "text": "Carbamoyl phosphate synthetase-2"
        },
        {
          "id": 2,
          "text": "Aspartate transcarbamoylase"
        },
        {
          "id": 3,
          "text": "Dihydroorotase"
        },
        {
          "id": 4,
          "text": "Dihydroorotate dehydrogenase"
        }
      ],
      "correct_choice_id": 4,
      "solution": "<p>The only mitochondrial step in pyrimidine synthesis is catalyzed by the enzyme <strong>dihydroorotate dehydrogenase.</strong></p>\n<p>Pyrimidine synthesis primarily happens in the <strong>liver</strong> in <strong>both</strong> cytoplasm and mitochondria. The conversion of<strong> dihydroorotic acid</strong> to <strong>orotic acid </strong>catalyzed by the enzyme dihydroorotate dehydrogenase is the only step that occurs in<strong> mitochondria. </strong>The rest of the reaction occurs in the cytoplasm.</p>\n<p><strong>CAD</strong> enzymes are <strong>multifunctional enzymes</strong> present in a <strong>single polypeptide chain</strong>. It includes:</p>\n<ul>\n<li>Carbamoyl phosphate synthetase-2</li>\n<li>Aspartate transcarbamoylase</li>\n<li>Dihydroorotase</li>\n</ul>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MD1211",
      "difficulty": "medium"
    },
    {
      "text": "The rate-limiting enzyme for pyrimidine synthesis in human is ______",
      "choices": [
        {
          "id": 1,
          "text": "Aspartate Transcarbamoylase"
        },
        {
          "id": 2,
          "text": "Carbamoyl Phosphate Synthetase I"
        },
        {
          "id": 3,
          "text": "Carbamoyl Phosphate Synthetase II"
        },
        {
          "id": 4,
          "text": "PRPP glutamyl amidotransferase"
        }
      ],
      "correct_choice_id": 3,
      "solution": "<p>In humans, the <strong>rate-limiting</strong> enzyme for pyrimidine synthesis is <strong>carbamoyl phosphate synthetase-II</strong> (CPS-II).</p>\n<p><strong>Carbamoyl phosphate synthetase II </strong>catalyzes the conversion of glutamine to carbamoyl phosphate. CPS-II is inhibited by<strong> UTP</strong> and activated by<strong> PRPP</strong>.</p>\n<p>Other options: </p>\n<p>Option A: Aspartate Transcarbamoylase is the rate-limiting enzyme for pyrimidine synthesis in bacteria<strong>(prokaryote)</strong>.</p>\n<p>Option B: Carbamoyl Phosphate Synthetase I is the rate-limiting enzyme of the<strong> urea cycle.</strong></p>\n<p>Option D: PRPP glutamyl amidotransferase is the rate-limiting enzyme of <strong>De Novo purine synthesis</strong>.</p><img src=\"https://dhmbxeygs57ff.cloudfront.net/uploads/6261d2a5262d4201afbb6469a0162bd9x1280x960.JPEG\" alt=\"Explanation Image\">",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MB2348",
      "difficulty": "medium"
    },
    {
      "text": "Which is the first true pyrimidine nucleotide formed in pyrimidine synthesis?",
      "choices": [
        {
          "id": 1,
          "text": "UDP"
        },
        {
          "id": 2,
          "text": "CTP"
        },
        {
          "id": 3,
          "text": "UMP"
        },
        {
          "id": 4,
          "text": "TMP"
        }
      ],
      "correct_choice_id": 3,
      "solution": "<p>The<strong> first</strong> <strong>true</strong> pyrimidine nucleotide formed in <strong>pyrimidine synthesis</strong> is <strong>U</strong><strong>MP.</strong></p>\n<p>OMP formed from orotic acid by the enzyme <strong>orotate phosphoribosyltransferase</strong> (OPRTase).<strong> OMP </strong>is then immediately <strong>decarboxylated</strong> using <strong>orotidylic acid decarboxylase</strong> to produce <strong>UMP</strong>. Nucleotides <strong>CTP</strong> and <strong>TMP</strong> are then formed subsequently from UMP via <strong>CTP synthetase</strong> and <strong>thymidylate synthase.</strong></p>\n<p>Methotrexate inhibits <strong>Dihydrofolate reductase</strong> (DHFR) which stops TMP synthesis. 5-Fluorouracil inhibits<strong> thymidylate synthase</strong>. <br />OPRTase and orotidylic acid decarboxylase are two enzymes which are considered as a single polypeptide enzyme - <strong>UMP synthase. </strong>Deficiency of UMP synthase leads to <strong>orotic aciduria.</strong></p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MB2350",
      "difficulty": "medium"
    },
    {
      "text": "Which of the following is not a  product of pyrimidine catabolism?",
      "choices": [
        {
          "id": 1,
          "text": "NH3"
        },
        {
          "id": 2,
          "text": "β-alanine"
        },
        {
          "id": 3,
          "text": "β-aminoisobutyrate"
        },
        {
          "id": 4,
          "text": "Uric acid"
        }
      ],
      "correct_choice_id": 4,
      "solution": "<p><strong>Uric acid</strong> is not a product of pyrimidine catabolism, it is a product of <strong>purine catabolism</strong>. All other options are products of pyrimidine catabolism.</p>\n<p>Unlike the <strong>low solubility products</strong> of <strong>purine</strong> catabolism, the catabolism of the pyrimidines forms <strong>highly water-soluble </strong>products, thus pyrimidine overproduction results in few clinical features.</p>\n<p><strong>Cytosine</strong> and <strong>uracil</strong> form β-alanine, CO2, and NH3. <strong>Thymine </strong>forms β-amino isobutyrate, CO,2 and NH3.</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MB2353",
      "difficulty": "medium"
    },
    {
      "text": "The blood report of a patient shows increased uric acid levels. Which of the following diagnosis can be ruled out?",
      "choices": [
        {
          "id": 1,
          "text": "von Gierke's disease"
        },
        {
          "id": 2,
          "text": "Xanthinuria"
        },
        {
          "id": 3,
          "text": "Lesch-Nyhan syndrome"
        },
        {
          "id": 4,
          "text": "Kelley-Seegmiller syndrome"
        }
      ],
      "correct_choice_id": 2,
      "solution": "<p>Hyperuricemia is not seen in <strong>xanthinuria.</strong></p>\n<p><strong>Xanthinuria </strong>occurs due to a defect in the enzyme <strong>xanthine oxidase</strong>. Xanthine oxidase catalyzes the conversion of<strong> hypoxanthine</strong> to <strong>xanthine</strong> and xanthine to <strong>uric acid. </strong>It is associated with<strong> hypouricemia </strong>and<strong> xanthine lithiasis</strong>.</p>\n<p><strong>Lesch-Nyhan syndrome</strong> is caused by complete deficiency of <strong>HGPRTase,</strong><strong> </strong>whereas <strong>Kelley-Seegmiller</strong> syndrome is caused by the partial deficiency of <strong>HGPRTase</strong>. Purines accumulate, causing <strong>hyperuricemia.</strong></p>\n<p>In <strong>von Gierke's disease</strong>, the oxidation of glucose-6-phosphate via the<strong> pentose phosphate pathway</strong> leads to increased production of ribose-5-phosphate which <strong>activates </strong>the <strong>de novo</strong> <strong>synthesis </strong>of <strong>purine nucleotides</strong>. Overproduction of these nucleotides leads to their degradation, which causes <strong>hyperuricemia</strong>.</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MD1213",
      "difficulty": "medium"
    },
    {
      "text": "An 11-month-old infant presented with growth failure and developmental delay. Her peripheral smear showed macrocytic anemia.  Vitamin B12 or folic acid levels in plasma were normal. No evidence of Transcobalmin -2 deficiency was found. The compound given in the picture is excreted in the urine. What is the most likely diagnosis?",
      "choices": [
        {
          "id": 1,
          "text": "Gout"
        },
        {
          "id": 2,
          "text": "Lesch Nyhan Syndrome"
        },
        {
          "id": 3,
          "text": "Xanthinuria"
        },
        {
          "id": 4,
          "text": "Orotic aciduria"
        }
      ],
      "correct_choice_id": 4,
      "solution": "<p>The given clinical picture is highly suggestive of<strong> orotic aciduria.</strong> The compound given in the image is <strong>orotic acid.</strong></p>\n<p>Orotic aciduria is a rare <strong>autosomal recessive</strong> condition. T<span>he deficiency of <strong>UMP synthase</strong> causes <strong>type-1 orotic aciduria</strong></span>. <strong>Type-2</strong> orotic aciduria is caused by the deficiency of <strong>orotidylate decarboxylase. </strong>It manifests usually in the<strong> first year</strong> of life and presents with <strong>growth failure, developmental retardation, megaloblastic anemia</strong> and increased urinary excretion of <strong>orotic acid.</strong></p>\n<p><strong>Severe megaloblastic anemia</strong> with <strong>normal</strong> serum B12 and folic acid levels suggests this condition. A presumptive diagnosis is made by checking increased urinary excretion of <strong>orotic acid. </strong>Confirmation is done by enzyme assays of transferase and decarboxylase of erythrocytes. The anemia only responds to the administration of <strong>uridine. </strong>Allopurinol and 6-azauridine may precipitate this condition.</p>\n<p>Other options: </p>\n<p>Option A and B: In gout and Lesch Nyhan syndrome <strong>uric acid</strong> crystals are excreted.</p>\n<p>Option C: In xanthinuria, <strong>xanthine</strong> crystals are excreted.</p>",
      "question_images": [
        "https://cdn1.dailyrounds.org/uploads/bd436c49aae84d4b84d8d23f4d0a3920.PNG"
      ],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MB2356",
      "difficulty": "medium"
    },
    {
      "text": "A 14 year old male is brought with the complaints of multiple hyperpigmented papules over the face and other sun exposed areas with persistent erythema. He had history of similar episodes since childhood. Which of the following mechanisms is likely to be defective in this condition?",
      "choices": [
        {
          "id": 1,
          "text": "Removal of mismatched base during DNA replication"
        },
        {
          "id": 2,
          "text": "Removal of oligonucleotides containing damaged bases by endonuclease"
        },
        {
          "id": 3,
          "text": "Removal of the altered base by base specific glycosylase"
        },
        {
          "id": 4,
          "text": "Repair of double stranded breaks"
        }
      ],
      "correct_choice_id": 2,
      "solution": "<p>The above given clinical findings is suggestive of <strong>xeroderma pigmentosum</strong>. Defect in the removal of oligonucleotides containing the damaged bases by endonucleases is seen in xeroderma pigmentosum.</p>\n<p>Xeroderma Pigmentosum (XP) is a rare <strong>autosomal recessive</strong> genetic disorder characterized by defective DNA repair which leads to clinical and cellular <strong>hypersensitivity to ultraviolet radiation </strong>and other carcinogenic agents.  </p>\n<p>Important <strong>clinical features</strong> are:</p>\n<p>Intense cutaneous photosensitivity, xerosis, poikiloderma, actinic keratosis, acute burning under minimal sun exposure, erythemas, hyperpigmented lentiginous macules, and malignant lesions in sun-exposed areas, including basocellular carcinoma, squamous cell carcinoma, and melanoma.  </p>\n<p>The final diagnosis of XP can be confirmed by special laboratory tests by examining the DNA damage repair in cells from cultures exposed to ultraviolet radiation. The most common tests are <strong>skin biopsy</strong> and <strong>culture of skin fibroblasts</strong>.  </p>\n<p>There is <strong>no cure</strong> for XP. Treatment consists of minimizing exposure to sunlight and regular dermatological care, as well as surgery for recurrent tumors excision. Patients should be <strong>followed up</strong> every <strong>3 months</strong>. <strong>Genetic counseling</strong> is important in a family that has an affected child and is considering having more children.</p><hr><h3>Related Pearl: Human Diseases of DNA Damage Repair</h3><table>\n<tbody>\n<tr>\n<td>\n<p><strong>DNA damage repair type</strong></p>\n</td>\n<td>\n<p><strong>Diseases</strong></p>\n</td>\n</tr>\n<tr>\n<td>\n<p>Defective Nonhomologous End Joining Repair (NHEJ)</p>\n</td>\n<td>\n<p>Severe combined immunodeficiency disease (SCID)</p>\n<p>Radiation sensitive severe combined immunodeficiency disease(RS-SCID)</p>\n</td>\n</tr>\n<tr>\n<td>\n<p>Defective Homologous Repair (HR)</p>\n</td>\n<td>\n<p>AT-like disorder (ATLD)</p>\n<p>Nijmegen breakage syndrome (NBS)</p>\n<p>Bloom syndrome (BS)</p>\n<p>Werner syndrome (WS)</p>\n<p>Rothmund-Thomson syndrome (RTS)</p>\n<p>Breast cancer suspectibility 1 and 2 (BRCA1, BRCA2)</p>\n</td>\n</tr>\n<tr>\n<td>\n<p>Defective DNA Nucleotide Excision Repair (NER)</p>\n</td>\n<td>\n<p>Xeroderma pigmentosum (XP)</p>\n<p>Cockayne syndrome (CS)</p>\n<p>Trichothiodystrophy (TTD)</p>\n</td>\n</tr>\n<tr>\n<td>\n<p>Defective DNA Base Excision Repair (BER)</p>\n</td>\n<td>\n<p>MUTYH-associated polyposis (MAP)</p>\n</td>\n</tr>\n<tr>\n<td>\n<p>Defective DNA Mismatch Repair (MMR)</p>\n</td>\n<td>\n<p>Hereditary nonpolyposis colorectal cancer (HNPCC)</p>\n</td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MC6261",
      "difficulty": "medium"
    }
  ]
}